Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease

Shots:

• The collaboration is focused on development of Larazotide for Alcoholic Liver Diseases (ALD), including severe alcoholic hepatitis
• Innovate will conduct an investor update on 17 Dec, 2018 for Larazotide, in celiac disease clinical program and NASH development strategy
• Larazotide (INN-202) is a synthetic eight amino acid peptide drug, completed P-II trial and expected to initiate P-III in H1’19 for celiac disease (previously planned to conduct in H2’18)

Click here to read full press release/ article | Ref: Innovate Pharmaceuticals | Image: Contract Pharma